PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer


FLORHAM PARK, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the appointment of Seth Van Voorhees, Ph.D. as its new Chief Financial Officer effective January 1, 2021.

Here is the original post:
PDS Biotechnology Appoints Seth Van Voorhees as Chief Financial Officer

Related Posts